Delayed methotrexate Elimination
Delayed methotrexate elimination in a affected person with main central nervous system lymphoma: A case report
What is thought and goal: Methotrexate (MTX) is a vital agent for the therapy of main central nervous system lymphomas (PCNSL) however must be given in massive doses by intravenous infusions to realize therapeutic concentrations within the cerebrospinal fluid. Nevertheless, co-administration with many medicine could delay the excretion of MTX which can trigger critical antagonistic results if the serum focus exceeds 0.1 µmol/L 72 h after an intravenous infusion.
Case abstract: A 67-year-old Japanese feminine with PCNSL was handled with high-dose MTX-based chemotherapy. The serum MTX focus 72 h post-infusion was 0.153 µmol/L when she was taking levofloxacin (LVFX) however <0.1 µmol/L 72 h after 4 subsequent infusions when she was not taking LVFX. She was given many different medicine however the timing of the quick course of LVFX and the truth that ciprofloxacin additionally delays MTX excretion means that LVFX was the trigger.
What’s new and conclusion: Co-administration of LVFX could delay the excretion of MTX. Due to this fact, serum concentrations of MTX needs to be monitored to assist stop and enhance the administration of probably critical MTX drug-drug interplay.
FRA10C Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725925 | ABM | 1.0 ug DNA | Ask for price |
FRA10D Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725931 | ABM | 1.0 ug DNA | Ask for price |
FRA10E Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725937 | ABM | 1.0 ug DNA | Ask for price |
FRA10F Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725943 | ABM | 1.0 ug DNA | Ask for price |
FRA10G Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725949 | ABM | 1.0 ug DNA | Ask for price |
FRA11A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725955 | ABM | 1.0 ug DNA | Ask for price |
FRA11B Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725961 | ABM | 1.0 ug DNA | Ask for price |
FRA11C Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725967 | ABM | 1.0 ug DNA | Ask for price |
FRA11D Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725973 | ABM | 1.0 ug DNA | Ask for price |
FRA11E Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725979 | ABM | 1.0 ug DNA | Ask for price |
FRA11F Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725985 | ABM | 1.0 ug DNA | Ask for price |
FRA11G Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725991 | ABM | 1.0 ug DNA | Ask for price |
FRA11H Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725997 | ABM | 1.0 ug DNA | Ask for price |
FRA11I Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726003 | ABM | 1.0 ug DNA | Ask for price |
FRA12A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726009 | ABM | 1.0 ug DNA | Ask for price |
FRA12B Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726015 | ABM | 1.0 ug DNA | Ask for price |
FRA12C Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726021 | ABM | 1.0 ug DNA | Ask for price |
FRA12D Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726027 | ABM | 1.0 ug DNA | Ask for price |
FRA12E Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726033 | ABM | 1.0 ug DNA | Ask for price |
FRA13A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726039 | ABM | 1.0 ug DNA | Ask for price |
FRA13B Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726045 | ABM | 1.0 ug DNA | Ask for price |
FRA13C Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726051 | ABM | 1.0 ug DNA | Ask for price |
FRA13D Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726057 | ABM | 1.0 ug DNA | Ask for price |
FRA14B Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726063 | ABM | 1.0 ug DNA | Ask for price |
FRA14C Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726069 | ABM | 1.0 ug DNA | Ask for price |
FRA15A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726075 | ABM | 1.0 ug DNA | Ask for price |
FRA16A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726081 | ABM | 1.0 ug DNA | Ask for price |
FRA16B Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726087 | ABM | 1.0 ug DNA | Ask for price |
FRA16C Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726093 | ABM | 1.0 ug DNA | Ask for price |
FRA16D Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726099 | ABM | 1.0 ug DNA | Ask for price |
FRA16E Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726105 | ABM | 1.0 ug DNA | Ask for price |
FRA17A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726111 | ABM | 1.0 ug DNA | Ask for price |
FRA17B Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726117 | ABM | 1.0 ug DNA | Ask for price |
FRA18A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726123 | ABM | 1.0 ug DNA | Ask for price |
FRA18B Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726129 | ABM | 1.0 ug DNA | Ask for price |
FRA18C Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726135 | ABM | 1.0 ug DNA | Ask for price |
FRA19A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726141 | ABM | 1.0 ug DNA | Ask for price |
FRA19B Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726147 | ABM | 1.0 ug DNA | Ask for price |
FRA20A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726153 | ABM | 1.0 ug DNA | Ask for price |
FRA20B Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726159 | ABM | 1.0 ug DNA | Ask for price |
FRA22A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726165 | ABM | 1.0 ug DNA | Ask for price |
FRA22B Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726171 | ABM | 1.0 ug DNA | Ask for price |
FRA2B Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725595 | ABM | 1.0 ug DNA | Ask for price |
FRA2C Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725601 | ABM | 1.0 ug DNA | Ask for price |
FRA2D Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725607 | ABM | 1.0 ug DNA | Ask for price |
FRA2E Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725613 | ABM | 1.0 ug DNA | Ask for price |
FRA2F Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725619 | ABM | 1.0 ug DNA | Ask for price |
FRA2G Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725625 | ABM | 1.0 ug DNA | Ask for price |
FRA2H Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725631 | ABM | 1.0 ug DNA | Ask for price |
FRA2I Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725637 | ABM | 1.0 ug DNA | Ask for price |
FRA2J Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725643 | ABM | 1.0 ug DNA | Ask for price |
FRA2K Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725649 | ABM | 1.0 ug DNA | Ask for price |
FRA3A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725655 | ABM | 1.0 ug DNA | Ask for price |
FRA3B Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725661 | ABM | 1.0 ug DNA | Ask for price |
FRA3C Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725667 | ABM | 1.0 ug DNA | Ask for price |
FRA3D Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725673 | ABM | 1.0 ug DNA | Ask for price |
FRA4A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725679 | ABM | 1.0 ug DNA | Ask for price |
FRA4B Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725685 | ABM | 1.0 ug DNA | Ask for price |
FRA4C Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725691 | ABM | 1.0 ug DNA | Ask for price |
FRA4D Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725697 | ABM | 1.0 ug DNA | Ask for price |
FRA5A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725703 | ABM | 1.0 ug DNA | Ask for price |
FRA5B Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725709 | ABM | 1.0 ug DNA | Ask for price |
FRA5C Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725715 | ABM | 1.0 ug DNA | Ask for price |
FRA5D Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725721 | ABM | 1.0 ug DNA | Ask for price |
FRA5E Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725727 | ABM | 1.0 ug DNA | Ask for price |
FRA5F Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725733 | ABM | 1.0 ug DNA | Ask for price |
FRA5G Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725739 | ABM | 1.0 ug DNA | Ask for price |
FRA6A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725745 | ABM | 1.0 ug DNA | Ask for price |
FRA6B Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725751 | ABM | 1.0 ug DNA | Ask for price |
FRA6C Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725757 | ABM | 1.0 ug DNA | Ask for price |
FRA6D Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725763 | ABM | 1.0 ug DNA | Ask for price |
FRA6E Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725769 | ABM | 1.0 ug DNA | Ask for price |
FRA6F Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725775 | ABM | 1.0 ug DNA | Ask for price |
FRA6G Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725781 | ABM | 1.0 ug DNA | Ask for price |
FRA7A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725787 | ABM | 1.0 ug DNA | Ask for price |
FRA7B Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725793 | ABM | 1.0 ug DNA | Ask for price |
FRA7C Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725799 | ABM | 1.0 ug DNA | Ask for price |
FRA7D Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725805 | ABM | 1.0 ug DNA | Ask for price |
FRA7E Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725811 | ABM | 1.0 ug DNA | Ask for price |
FRA7F Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725817 | ABM | 1.0 ug DNA | Ask for price |
FRA7G Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725823 | ABM | 1.0 ug DNA | Ask for price |
FRA7H Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725829 | ABM | 1.0 ug DNA | Ask for price |
FRA7I Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725835 | ABM | 1.0 ug DNA | Ask for price |
FRA7J Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725841 | ABM | 1.0 ug DNA | Ask for price |
FRA8A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725847 | ABM | 1.0 ug DNA | Ask for price |
FRA8B Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725853 | ABM | 1.0 ug DNA | Ask for price |
FRA8C Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725859 | ABM | 1.0 ug DNA | Ask for price |
FRA8D Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725865 | ABM | 1.0 ug DNA | Ask for price |
FRA8E Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725871 | ABM | 1.0 ug DNA | Ask for price |
FRA9A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725877 | ABM | 1.0 ug DNA | Ask for price |
FRA9B Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725883 | ABM | 1.0 ug DNA | Ask for price |
FRA9C Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725889 | ABM | 1.0 ug DNA | Ask for price |
FRA9D Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725895 | ABM | 1.0 ug DNA | Ask for price |
FRA9E Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725901 | ABM | 1.0 ug DNA | Ask for price |
FRA9F Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725907 | ABM | 1.0 ug DNA | Ask for price |
FRA1A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725511 | ABM | 1.0 ug DNA | Ask for price |
FRA1B Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725517 | ABM | 1.0 ug DNA | Ask for price |
FRA1C Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725523 | ABM | 1.0 ug DNA | Ask for price |
FRA1D Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725529 | ABM | 1.0 ug DNA | Ask for price |
FRA1E Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725535 | ABM | 1.0 ug DNA | Ask for price |
FRA1F Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725541 | ABM | 1.0 ug DNA | Ask for price |
FRA1G Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725547 | ABM | 1.0 ug DNA | Ask for price |
FRA1H Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725553 | ABM | 1.0 ug DNA | Ask for price |
FRA1I Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725559 | ABM | 1.0 ug DNA | Ask for price |
FRA1J Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725565 | ABM | 1.0 ug DNA | Ask for price |
FRA1K Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725571 | ABM | 1.0 ug DNA | Ask for price |
FRA1L Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725577 | ABM | 1.0 ug DNA | Ask for price |
FRA1M Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725583 | ABM | 1.0 ug DNA | Ask for price |
FRA2A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV725589 | ABM | 1.0 ug DNA | Ask for price |
FRAG1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810931 | ABM | 1.0 ug DNA | EUR 379.2 |
FRAXA Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726177 | ABM | 1.0 ug DNA | Ask for price |
FRAXB Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726183 | ABM | 1.0 ug DNA | Ask for price |
FRAXC Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726189 | ABM | 1.0 ug DNA | Ask for price |
FRAXD Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726195 | ABM | 1.0 ug DNA | Ask for price |
FRAXE Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726201 | ABM | 1.0 ug DNA | Ask for price |
FRAXF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV726207 | ABM | 1.0 ug DNA | Ask for price |
CS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV709015 | ABM | 1.0 ug DNA | EUR 379.2 |
HP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV703723 | ABM | 1.0 ug DNA | EUR 540 |
C5 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV704425 | ABM | 1.0 ug DNA | EUR 540 |
S7 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV747681 | ABM | 1.0 ug DNA | Ask for price |
NP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV814303 | ABM | 1.0 ug DNA | EUR 540 |
P1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV739461 | ABM | 1.0 ug DNA | Ask for price |
NA Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV735849 | ABM | 1.0 ug DNA | Ask for price |
NM Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV736287 | ABM | 1.0 ug DNA | Ask for price |
MS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV734271 | ABM | 1.0 ug DNA | Ask for price |
IV Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV730179 | ABM | 1.0 ug DNA | Ask for price |
XM Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV756075 | ABM | 1.0 ug DNA | Ask for price |
XS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV756093 | ABM | 1.0 ug DNA | Ask for price |
HGF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV701983 | ABM | 1.0 ug DNA | EUR 540 |
C8A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV702505 | ABM | 1.0 ug DNA | EUR 540 |
MIP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV706507 | ABM | 1.0 ug DNA | EUR 540 |
AEN Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV707161 | ABM | 1.0 ug DNA | EUR 379.2 |
AEN Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV707167 | ABM | 1.0 ug DNA | EUR 379.2 |
AGK Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV707191 | ABM | 1.0 ug DNA | EUR 379.2 |
ALB Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV707275 | ABM | 1.0 ug DNA | EUR 379.2 |
ANG Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV707329 | ABM | 1.0 ug DNA | EUR 379.2 |
ATM Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV707659 | ABM | 1.0 ug DNA | EUR 379.2 |
BID Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV707851 | ABM | 1.0 ug DNA | EUR 379.2 |
BMF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV707875 | ABM | 1.0 ug DNA | EUR 379.2 |
BMF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV707881 | ABM | 1.0 ug DNA | EUR 379.2 |
CA8 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV708259 | ABM | 1.0 ug DNA | EUR 379.2 |
CA8 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV708265 | ABM | 1.0 ug DNA | EUR 379.2 |
CBS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV708343 | ABM | 1.0 ug DNA | EUR 379.2 |
CBS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV708349 | ABM | 1.0 ug DNA | EUR 379.2 |
CGA Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV708673 | ABM | 1.0 ug DNA | EUR 379.2 |
CKB Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV708757 | ABM | 1.0 ug DNA | EUR 379.2 |
CRK Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV708991 | ABM | 1.0 ug DNA | EUR 379.2 |
CRP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV708997 | ABM | 1.0 ug DNA | EUR 379.2 |
CRP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV709003 | ABM | 1.0 ug DNA | EUR 379.2 |
DTL Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV709471 | ABM | 1.0 ug DNA | EUR 379.2 |
LY9 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV705295 | ABM | 1.0 ug DNA | EUR 540 |
DUT Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV705463 | ABM | 1.0 ug DNA | EUR 540 |
NPL Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV705589 | ABM | 1.0 ug DNA | EUR 540 |
BMF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV705643 | ABM | 1.0 ug DNA | EUR 540 |
FTO Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV706003 | ABM | 1.0 ug DNA | EUR 540 |
UBB Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV716533 | ABM | 1.0 ug DNA | EUR 379.2 |
CCT Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720669 | ABM | 1.0 ug DNA | Ask for price |
CCV Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720723 | ABM | 1.0 ug DNA | Ask for price |
Sp2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV715321 | ABM | 1.0 ug DNA | EUR 379.2 |
Sp2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV715327 | ABM | 1.0 ug DNA | EUR 379.2 |
Syk Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV715609 | ABM | 1.0 ug DNA | EUR 379.2 |
SLN Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV702973 | ABM | 1.0 ug DNA | EUR 540 |
CRP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV703483 | ABM | 1.0 ug DNA | EUR 540 |
NPL Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV703699 | ABM | 1.0 ug DNA | EUR 540 |
LY9 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV703819 | ABM | 1.0 ug DNA | EUR 540 |
AIC Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV718395 | ABM | 1.0 ug DNA | Ask for price |
AOM Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV718869 | ABM | 1.0 ug DNA | Ask for price |
ATD Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV719175 | ABM | 1.0 ug DNA | Ask for price |
FGA Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV704107 | ABM | 1.0 ug DNA | EUR 540 |
NNT Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV704257 | ABM | 1.0 ug DNA | EUR 540 |
WAC Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV716731 | ABM | 1.0 ug DNA | EUR 379.2 |
AFA Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV718317 | ABM | 1.0 ug DNA | Ask for price |
TK1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV715879 | ABM | 1.0 ug DNA | EUR 379.2 |
TTK Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV716389 | ABM | 1.0 ug DNA | EUR 379.2 |
ST2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV749655 | ABM | 1.0 ug DNA | EUR 686.4 |
A case report of secondary bilateral orbital lymphoma in a toddler
Lymphoma is without doubt one of the most typical cancers of the orbital and lacrimal glands, after squamous cell carcinoma and melanoma. Based mostly on cell origin, most lymphoma circumstances are categorized as non-Hodgkin lymphoma. Orbital lymphoma may be both main or secondary. The scientific manifestations of lymphoma are various, with the most typical signs being bilateral or unilateral proptosis, restricted eye motility, swelling, ache, adjustments in visible acuity, and diplopia. On this article, we describe the case of a 6-year-old male who offered with bilateral fast orbital swelling for 10 days. This affected person underwent surgical biopsy, and the ultimate prognosis was bilateral orbital secondary non-Hodgkin lymphoma.
Therapy patterns and outcomes of older sufferers with mantle cell lymphoma in an Asian inhabitants
Background: Important progress has been made within the therapy outcomes of mantle cell lymphoma (MCL) for the reason that introduction of cytarabine and rituximab in fashionable regimens. Nevertheless, older sufferers could not readily tolerate these brokers nor derive profit. We investigated the affect of age on therapy patterns and scientific outcomes of MCL sufferers in an Asian inhabitants.
Strategies: A retrospective research was carried out on sufferers (n = 66) identified with MCL on the Nationwide Most cancers Centre Singapore between 1998 and 2018. The median follow-up length was 40 months. Survival analyses have been carried out utilizing the Kaplan-Meier methodology and multivariate Cox proportional fashions.
Outcomes: The median age of the cohort was 59 years (vary, 26-84), with a male predominance (73%). The bulk (86%) had superior stage 3-Four illness at prognosis. In contrast with youthful sufferers, older sufferers aged ≥60 years (n = 32; 48.5%) offered extra incessantly with B-symptoms (75% vs 38%, p = 0.0028), anaemia (75% vs 35%, p = 0.0013), and carried greater prognostic danger scores (sMIPI excessive danger 84% vs 56%, p = 0.016). Non-cytarabine-based induction chemotherapy was extra generally administered in older sufferers (76% vs 32%, p = 0.0012). The 5-year total survival (OS) and progression-free survival (PFS) was 68 and 25% respectively. In a multivariable mannequin, older age (HR 3.42, 95%CI 1.48-7.92, p = 0.004) and anemia (HR 2.56, 95%CI 1.10-5.96, p = 0.029) have been independently related to poorer OS whereas older age (HR 2.24, 95%CI 1.21-4.14, p = 0.010) and hypoalbuminemia (HR 2.20, 95%CI 1.17-4.13, p = 0.014) have been independently related to poorer PFS. In an exploratory evaluation, upkeep rituximab following induction chemotherapy improved PFS in youthful sufferers, with median PFS of 131 months and 45 months with or with out upkeep remedy respectively (HR 0.39, 95%CI 0.16-0.93, p = 0.035). In distinction, no survival profit was noticed in older sufferers.
Conclusions: We demonstrated in our evaluation that older sufferers with MCL could harbor antagonistic scientific options and should not derive profit from upkeep rituximab, highlighting the necessity for additional analysis on this space of want.
Utility of the Euro Clonality next-generation sequencing-based marker screening method to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma sufferers: first knowledge from the Fondazione Italiana Linfomi MCL0208 trial
Minimal residual illness (MRD) decided by traditional polymerase chain response (PCR) strategies is a robust consequence predictor in mantle cell lymphoma (MCL). Nonetheless, some technical pitfalls can scale back the speed of of molecular markers. Due to this fact, we utilized the EuroClonality-NGS IGH (next-generation sequencing immunoglobulin heavy chain) methodology (beforehand printed in acute lymphoblastic leukaemia) to 20 MCL sufferers enrolled in an Italian section III trial sponsored by Fondazione Italiana Linfomi. Outcomes from this preliminary investigation present that EuroClonality-NGS IGH methodology is possible within the MCL context, detecting a molecular IGH goal in 19/20 investigated circumstances, permitting MRD monitoring additionally in these sufferers missing a molecular marker for classical screening approaches.
The position of BAFF and G-CSF for rituximab-induced late-onset neutropenia (LON) in lymphomas
Mechanisms for late-onset neutropenia (LON) after rituximab therapy are poorly outlined each for non-Hodgkin lymphoma (NHL) and for autoimmune issues. We carried out a case-control evaluation of a potential cohort of 169 evaluable consecutive rituximab-treated NHL sufferers to evaluate cytokines concerned in neutro- and lymphopoiesis (G-CSF, SDF1, BAFF, APRIL) and irritation (CRP) as attainable LON mechanisms. Fifteen sufferers (9%) developed LON (peripheral blood /PB/ absolute neutrophil counts /ANC/ < 0.5 G/L, all with marked depletion of CD20+ B-lymphocytes in bone marrows); they have been in contrast with 20 matched NHL controls with out LON. At begin of LON, considerably greater PB G-CSF and BAFF ranges (P = 0.0004 and 0.006, respectively), in addition to CRP rises have been famous in comparison with controls; these G-CSF and BAFF and most CRP values returned to ranges of the controls in post-LON samples.
G-CSF (however not BAFF) adjustments correlated to CRP rises (however to not ANC ranges). BAFF ranges correlated considerably to absolute monocyte counts and PB massive granular lymphocyte counts (however to not ANC, C-CSF or CRP values). No adjustments of SDF1 or APRIL ranges have been famous. Neither LON circumstances nor controls displayed anti-neutrophil autoantibodies. Collectively, LON in NHL sufferers was timewise associated to transient bursts of blood G-CSF and BAFF concentrations, suggesting that these neutro- and lymphopoiesis progress elements play a task in emergence of rituximab-induced LON, and that irritation could also be a set off for G-CSF manufacturing throughout LON.
